Related Experiment Video
Updated: Jan 5, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
A Single-Step, High-Dose Selection Scheme Reveals Distinct Mechanisms of Acquired Resistance to Oncogenic Kinase
Kenneth J Finn1, Scott E Martin2, Jeff Settleman3
1Calico Life Sciences LLC, South San Francisco, California.
Abstract:
Despite the remarkable clinical efficacy demonstrated by molecularly targeted cancer therapeutics, the benefits are typically temporary due to the emergence of acquired drug resistance. This has spurred a massive effort by the cancer research community to identify mechanisms used by cancer cells to evade treatment. Among the various methodologies developed and employed to identify such mechanisms, the most commonly used approach has been to model acquired resistance by exposing cancer cells in culture to gradually increasing concentrations of drug over an extended period of time. Here, we employed a less commonly used variation on this approach, wherein resistant cells are selected by immediately exposing cancer cells to a continuous, high concentration of drug. Using this approach, we isolated clones representing three distinct mechanisms of resistance to inhibition of MET kinase activity from a single clonally derived cancer cell line. The emergent clones had acquired resistance through engagement of alternative receptor tyrosine kinases either through upregulation of FGF3 or HBEGF or increased MAPK signaling through an activating V600E mutation in BRAF. Importantly, these mechanisms were not identified using the conventional "ramp-up" approach in previous studies that employed the same cell line. These results suggest that the particular nature of the selection scheme employed in cell culture modeling studies can determine which potential resistance mechanisms are identified and which ones may be missed, highlighting the need for careful consideration of the specific approach used to model resistance in cultured cells. SIGNIFICANCE: Through modeling resistance to MET kinase inhibition in cultured cancer cells using single-step, high-dose selection, these findings highlight that the specific nature of the selection protocol impacts which resistance mechanisms are identified.See related commentary by Floros et al., p. 25.
Insights
Modeling acquired drug resistance in cancer cells using a high-dose, single-step selection method revealed distinct resistance mechanisms not found with conventional gradual exposure. This highlights how selection methods impact identified cancer drug resistance pathways.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Acquired drug resistance limits the long-term effectiveness of molecularly targeted cancer therapies.
- Identifying resistance mechanisms is crucial for developing strategies to overcome treatment evasion.
Purpose of the Study:
- To investigate if a single-step, high-dose drug selection method identifies different cancer drug resistance mechanisms compared to conventional gradual exposure.
- To characterize novel resistance mechanisms to MET kinase inhibitors.
Main Methods:
- Exposing a single clonally derived cancer cell line to a continuous, high concentration of MET kinase inhibitor.
- Isolating and analyzing resistant clones to determine the underlying mechanisms of acquired resistance.
Main Results:
- Three distinct resistance mechanisms were identified: upregulation of FGF3 or HBEGF, and increased MAPK signaling via a BRAF V600E mutation.
- These mechanisms were not detected using the conventional gradual drug concentration increase (ramp-up) method in prior studies with the same cell line.
- The selection scheme significantly influenced the types of resistance mechanisms identified.
Conclusions:
- The method used to model acquired resistance in cell culture critically impacts the identification of specific resistance mechanisms.
- Employing diverse selection strategies, including single-step high-dose exposure, is essential for a comprehensive understanding of cancer drug resistance.
- This study underscores the need for careful consideration of experimental design in resistance modeling to uncover all potential evasion pathways.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity
mTOR Signaling and Cancer Progression
The mTOR pathway or the...